Source comparison
TBI Recovery Peptides 2026 Update: Comparison Table
Cerebrolysin Multi-neurotrophic factor mimicry (BDNF, NGF, CNTF) Enters via transient BBB disruption in acute phase Within 6–12 hours Increases doublecortin+ cells by 35–50% in hippocampus (rodent models) Most effective in acute window; requires IV administrat
This comparison does not assign a generated winner or score.
- Cerebrolysin
- Multi-neurotrophic factor mimicry (BDNF, NGF, CNTF)
- Enters via transient BBB disruption in acute phase
- Within 6–12 hours
- Increases doublecortin+ cells by 35–50% in hippocampus (rodent models)
- Most effective in acute window; requires IV administration; strongest clinical trial data for stroke/TBI
- Dihexa
- HGF/c-Met pathway activation → synaptogenesis
- Crosses intact BBB (lipophilic, 750 Da)
- 1–4 weeks (subacute phase)
- 7–10× potency vs BDNF in dendritic spine density (hippocampal slices)
- Orally active; works after BBB reseals; limited human data; high research interest
- P21
- CNTF receptor agonism → neuronal survival and myelination
- Independent BBB crossing (verified via radiotracer studies)
- Increases synaptic density 40–60% in cortex (rodent CCI models)
- Crosses BBB without injury; suitable for chronic recovery; no human trials yet
- Thymalin
- Immune modulation (reduces microglial activation, lowers IL-6/TNF-α)
- Indirect. Targets peripheral immune cells infiltrating via disrupted BBB
- Within 24–72 hours
- Reduces neuroinflammation by 30–40%; secondary neurogenesis support
- Immunomodulatory rather than neurotrophic; best in acute inflammatory phase